Multiple SclerosisNCT02851342
GTA-MEG as a Biomarker for Cognition in MS
An observational study of Multiple Sclerosis, run by Universitair Ziekenhuis Brussel at 1 site in Belgium.
Trial summary
In this study, 100 persons with Multiple Sclerosis and 50 matched controls will be examined with magnetoencephalography (MEG), magnetic resonance imaging (MRI) and cognitive tests. Read more about this study
- Who is it for?
- Ages 18 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Multiple Sclerosis
- How many people
- 159 participants
- Where
- 1 siteBelgium
- Study dates
- Apr 2016to Jan 2019
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Study population: patients with multiple sclerosis
Who may be able to join
- Multiple sclerosis according to the modified McDonald criteria
- Expanded Disability Status Scale (EDSS) below 6.0
- Providing informed consent
- Age between 18 and 55 years
Who cannot join
- Major medical or psychiatric pathology that potentially influences cognition
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Graph-theoretical Analysis of Magnetoencephalographic Recordings as a Biomarker for Cognitive Deterioration in Multiple Sclerosis
In this study, 100 persons with Multiple Sclerosis and 50 matched controls will be examined with magnetoencephalography (MEG), magnetic resonance imaging (MRI) and cognitive tests. The primary hypothesis for the study is: Interhemispheric connectivity, determined using graph theoretic analysis (GTA) on source-reconstructed MEG data, is a biomarker for cognitive deterioration in MS, which has value at the individual patient level.
Read the detailed description
Procedures
Clinical assessment
- Disease type (Progressive onset/Relapsing onset)
- Disease phase (onset, relapsing remitting, secondary progressive, …)
- EDSS measurement (standard in the neurological examination)
- Time since last relapse (important for the exclusion criteria)
- Medication
- Level of education
- Pre-morbid Intelligence Quotient (IQ)
Symbol Digit Modalities Test (SDMT) - screening
- General
- In the final design of this study, the investigators will screen our patient group using the Symbol Digit Modalities Test (SDMT), a fast (5 min) and easy test that has been shown to be predictive of general cognitive impairment in MS probably due to the importance of information processing speed in cognitive deterioration in MS.
- This screening procedure will allow us to include an 'enriched' sample of MS patients; i.e. including patients with different cognitive abilities will allow us to assess correlations between brain network organization and cognition over a broader range of cognitive abilities.
MEG/EEG assessment
- General
- The subjects are asked to come to the MEG unit in the Université libre de Bruxelles (ULB) Erasmus Hospital in Anderlecht
- MEG measurements will be obtained using a Neuromag-306 Vector View system (Elekta). This scanner has 306 channels: 102 pairs of orthogonal planar gradiometers and 102 magnetometers. To aid artifact detection, electrooculograms (EOG) and electrocardiograms (ECG) were also recorded. Sampling frequency is 1000 Hertz (HZ).
- Subjects will be monitored for excessive eye-blinks. Although methods as independent component analysis (ICA) can remove these artefacts to some extent, too many eye-blinks may render the subsequent analyses impossible.
- Preparing the subject for the MEG assessment takes about 45 min.
- The patient's head movement will be continuously monitored.
- Resting-state
- Eyes Open
- 10 min
- Subjects will be asked to pay attention to a fixation cross
- Eyes Closed
- 10 min
- Subjects will be asked not to fall asleep
- Adjusted SDMT
- In this experiment, the patients are shown a code that links the numbers 1-9 to a certain symbol. For each trial, they also see one example that links a number to a symbol and they are asked to press the LEFT button if they think the example conforms with the presented code and the RIGHT button if they think otherwise. Subjects will be given a maximum of 6 s for each decision to be made and response timings will be recorded. The code that is presented varies with every example. This computerized set up of the SDMT was kindly provided by prof. Rypma. There is a pause of 2s between every decoding task. A total of 256 stimuli are presented, half of which are correct. The design follows the design by Leavitt et al. very closely (except for variable the interstimulus interval- 4,8,12 s - that was fixed to 3s in this design. Depending on the speed at which the subjects answers, this paradigm is expected to last between 9 and 10 min.
- Practice trial
- The subjects are shown 10 trials and their response is monitored. In this step, the researcher checks if the subject understands the paradigm.
- Actual paradigm
- The patients will be shown 256 trials, 50 % of which are correct.
- The total time for this experiment (at a speed of 2s per decision is : 9 min).
- The subjects won't receive any feedback from this part.
- A small break of 10 minutes in order not to fatigue the subjects too much.
- Auditory P300 paradigm
- The subjects are asked to press a button when they hear a high-pitched tone among a series of standard tones. The interstimulus interval will randomly shift between 1 and 1.5 s.
- Practice trial
- Subjects will first hear the standard tone 10 times (1000 Hz)
- Subjects will hear the target (high-pitched, 1500 Hz) tone 2 times
- Subjects will hear the distractor tone (500 Hz) 2 times
- The interstimulus interval will be sampled from the same distribution as the interstimulus interval used in the actual test
- Patients are not asked to press any buttons in this part.
- Actual test
- The subjects will hear a series of 400 tones. The total test time is therefore 8m20.
- 80 % of the tones will be frequent tones
- 10 % of the tones will be target tones, for which the subjects are asked to press a button
- 10 % of the tones will be distractor tones. Subjects are asked not to press any button in case of these distractor tones.
- The subjects won't get any feedback on their performance
- N-back test
- In the N-back test, a subjects sees a series of numbers (1-4) and is asked to compare the current stimulus to the N'th previous stimulus. In the case of a zero-back experiment, the subjects are asked to press a button when they see a certain number (e.g. 2).
- The experiment is designed as follows. There are three conditions imposing different loads on working memory (0-,1- and 2-back tasks). Each block lasts 30 s and there are eight blocks for each condition. The total registration time is therefore 12 min. The experiment is designed in agreement with the literature.
- Before the actual experiment, there will be a small practice trial including the three blocks (0-, 1- and 2-back task). This lasts approximately 2 min.
- Possible confounders:
- General:
- These confounders are to be administered right after the MEG recordings.
- These confounders are important as they may influence the cognitive results obtained during the MEG.
- Depression (Beck Depression Inventory)
- Fatigue (Fatigue scale for Motor and Cognitive Functions, FSMC)
- Brief International Cognitive Assessment for MS (BICAMS)
- (2) MRI assessment
- The informed consent asks for permission to analyse the T1 and T2 image, two images included in the standard clinical protocol, in the data analysis for the study. Furthermore, we will acquire and analyse a diffusor tensor imaging (DTI) measurement and a resting-state functional MRI image.
- Conditions
- Multiple Sclerosis
- Keywords
- Cognition, MEG
- Medical subject headings
- Multiple Sclerosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| MS | patients with multiple sclerosis | |
| CO | matched control subjects |
What is being measured
The primary outcome is the main question the study is designed to answer.
MEG Contrasts of parameter estimates (COPE)
Contrasts (first-level or group-level) of parameter estimates based on averaged measured magnetic activity.
Measured: 0 to 1000 msec post stimulus
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Aug 2016 (estimated)
- Study startApr 2016
- Primary completionJan 2018
- Study completionJan 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Multiple SclerosisStudies of the same condition, open and under way.
- More trials run by Universitair Ziekenhuis BrusselThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 159 participants (actual)
Sponsor and investigators
- Lead sponsor
- Universitair Ziekenhuis Brussel
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02851342
- Sponsor's protocol ID
- BRUMEG
- Status last verified
- Nov 2020
- First submitted
- 25 Jul 2016
- Last updated
- 10 Nov 2020
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Nov 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Graph-theoretical Analysis of Magnetoencephalographic Recordings as a Biomarker for Cognitive Deterioration in Multiple Sclerosis
- ClinicalTrials.gov ID
- NCT02851342
- Acronym / sponsor ID
- BRUMEG
- Conditions
- Multiple Sclerosis
- Keywords
- Cognition, MEG
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 159 participants (actual)
- Lead sponsor
- Universitair Ziekenhuis BrusselUniversity, hospital or other
- Study start
- Apr 2016
- Primary completion
- Jan 2018 (actual)
- Study completion
- Jan 2019 (actual)
- First posted
- 1 Aug 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In this study, 100 persons with Multiple Sclerosis and 50 matched controls will be examined with magnetoencephalography (MEG), magnetic resonance imaging (MRI) and cognitive tests. The primary hypothesis for the study is: Interhemispheric connectivity, determined using graph theoretic analysis (GTA) on source-reconstructed MEG data, is a biomarker for cognitive deterioration in MS, which has value at the individual patient level.
Detailed description
Procedures
Clinical assessment
- Disease type (Progressive onset/Relapsing onset)
- Disease phase (onset, relapsing remitting, secondary progressive, …)
- EDSS measurement (standard in the neurological examination)
- Time since last relapse (important for the exclusion criteria)
- Medication
- Level of education
- Pre-morbid Intelligence Quotient (IQ)
Symbol Digit Modalities Test (SDMT) - screening
- General
- In the final design of this study, the investigators will screen our patient group using the Symbol Digit Modalities Test (SDMT), a fast (5 min) and easy test that has been shown to be predictive of general cognitive impairment in MS probably due to the importance of information processing speed in cognitive deterioration in MS.
- This screening procedure will allow us to include an 'enriched' sample of MS patients; i.e. including patients with different cognitive abilities will allow us to assess correlations between brain network organization and cognition over a broader range of cognitive abilities.
MEG/EEG assessment
- General
- The subjects are asked to come to the MEG unit in the Université libre de Bruxelles (ULB) Erasmus Hospital in Anderlecht
- MEG measurements will be obtained using a Neuromag-306 Vector View system (Elekta). This scanner has 306 channels: 102 pairs of orthogonal planar gradiometers and 102 magnetometers. To aid artifact detection, electrooculograms (EOG) and electrocardiograms (ECG) were also recorded. Sampling frequency is 1000 Hertz (HZ).
- Subjects will be monitored for excessive eye-blinks. Although methods as independent component analysis (ICA) can remove these artefacts to some extent, too many eye-blinks may render the subsequent analyses impossible.
- Preparing the subject for the MEG assessment takes about 45 min.
- The patient's head movement will be continuously monitored.
- Resting-state
- Eyes Open
- 10 min
- Subjects will be asked to pay attention to a fixation cross
- Eyes Closed
- 10 min
- Subjects will be asked not to fall asleep
- Adjusted SDMT
- In this experiment, the patients are shown a code that links the numbers 1-9 to a certain symbol. For each trial, they also see one example that links a number to a symbol and they are asked to press the LEFT button if they think the example conforms with the presented code and the RIGHT button if they think otherwise. Subjects will be given a maximum of 6 s for each decision to be made and response timings will be recorded. The code that is presented varies with every example. This computerized set up of the SDMT was kindly provided by prof. Rypma. There is a pause of 2s between every decoding task. A total of 256 stimuli are presented, half of which are correct. The design follows the design by Leavitt et al. very closely (except for variable the interstimulus interval- 4,8,12 s - that was fixed to 3s in this design. Depending on the speed at which the subjects answers, this paradigm is expected to last between 9 and 10 min.
- Practice trial
- The subjects are shown 10 trials and their response is monitored. In this step, the researcher checks if the subject understands the paradigm.
- Actual paradigm
- The patients will be shown 256 trials, 50 % of which are correct.
- The total time for this experiment (at a speed of 2s per decision is : 9 min).
- The subjects won't receive any feedback from this part.
- A small break of 10 minutes in order not to fatigue the subjects too much.
- Auditory P300 paradigm
- The subjects are asked to press a button when they hear a high-pitched tone among a series of standard tones. The interstimulus interval will randomly shift between 1 and 1.5 s.
- Practice trial
- Subjects will first hear the standard tone 10 times (1000 Hz)
- Subjects will hear the target (high-pitched, 1500 Hz) tone 2 times
- Subjects will hear the distractor tone (500 Hz) 2 times
- The interstimulus interval will be sampled from the same distribution as the interstimulus interval used in the actual test
- Patients are not asked to press any buttons in this part.
- Actual test
- The subjects will hear a series of 400 tones. The total test time is therefore 8m20.
- 80 % of the tones will be frequent tones
- 10 % of the tones will be target tones, for which the subjects are asked to press a button
- 10 % of the tones will be distractor tones. Subjects are asked not to press any button in case of these distractor tones.
- The subjects won't get any feedback on their performance
- N-back test
- In the N-back test, a subjects sees a series of numbers (1-4) and is asked to compare the current stimulus to the N'th previous stimulus. In the case of a zero-back experiment, the subjects are asked to press a button when they see a certain number (e.g. 2).
- The experiment is designed as follows. There are three conditions imposing different loads on working memory (0-,1- and 2-back tasks). Each block lasts 30 s and there are eight blocks for each condition. The total registration time is therefore 12 min. The experiment is designed in agreement with the literature.
- Before the actual experiment, there will be a small practice trial including the three blocks (0-, 1- and 2-back task). This lasts approximately 2 min.
- Possible confounders:
- General:
- These confounders are to be administered right after the MEG recordings.
- These confounders are important as they may influence the cognitive results obtained during the MEG.
- Depression (Beck Depression Inventory)
- Fatigue (Fatigue scale for Motor and Cognitive Functions, FSMC)
- Brief International Cognitive Assessment for MS (BICAMS)
- (2) MRI assessment
- The informed consent asks for permission to analyse the T1 and T2 image, two images included in the standard clinical protocol, in the data analysis for the study. Furthermore, we will acquire and analyse a diffusor tensor imaging (DTI) measurement and a resting-state functional MRI image.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| MS | – | –patients with multiple sclerosis |
| CO | – | –matched control subjects |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- patients with multiple sclerosis
Key inclusion criteria (4 listed)
- Multiple sclerosis according to the modified McDonald criteria
- Expanded Disability Status Scale (EDSS) below 6.0
- Providing informed consent
- Age between 18 and 55 years
Key exclusion criteria (1 listed)
- Major medical or psychiatric pathology that potentially influences cognition
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
MEG Contrasts of parameter estimates (COPE)
Time frame: 0 to 1000 msec post stimulus
Contrasts (first-level or group-level) of parameter estimates based on averaged measured magnetic activity.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Nov 2020.
- Individual participant dataSharing planned: No
Related trials for Multiple Sclerosis
RecruitingPhase 2
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
Multiple Sclerosis
RecruitingObservational study
Pain Phenotypes in Individuals With Multiple Sclerosis
Multiple Sclerosis, Chronic Pain
Not yet recruiting
Evaluating the Effect of the Zeen Mobility Device on Clinical Practicality, Safety, and Impact (Via Assessments of Walking, Standing Tolerance, Balance, Endurance, Effort, and Participation in Daily Tasks) in an Outpatient Rehabilitation Setting for Individuals With Mobility Impairments.
Stroke, Parkinson's Disease (PD)
RecruitingPhase 3
Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis
Multiple Sclerosis
RecruitingPhase 2
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis
Multiple Sclerosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Multiple Sclerosis, run by Universitair Ziekenhuis Brussel at 1 site in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Nov 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
MEG Contrasts of parameter estimates (COPE) (time frame: 0 to 1000 msec post stimulus). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Nov 2020.